Cerebrolysin in SAH (Subarachnoidal Haemorrhage) - Observational Study

Pomeranian Medical University Szczecin47 enrolled

Overview

Subarachnoid haemorrhage often affects people in middle age and is associated with high mortality or neurological damage. In recent years, advances in surgical techniques have im-proved the mortality rate. However, there is still need for the research for the optimal possible final effect of treatment. In our study, we've decided to examine the effect of a multimodal approach including Cerebrolysin in the supportive treatment of patients. We've examined the supply of neuroprotective drugs and neuromonitoring.

Study Type

OBSERVATIONAL

Enrollment

Conditions

SAH (Subarachnoid Hemorrhage)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * age \>18 years old, diagnosis of SAH, treatment in ICU conditions Exclusion Criteria: * age \<18 years, medical history of allergy to Cerebrolysin, acute renal failure, pregnancy, multi organ trauma, death within 48 hours after admission

Locations (1)

Pomeranian Medical University, University Hospital no.1

Szczecin, Poland

Outcomes

Primary Outcomes

GOS Glasgow Outcome Scale

Glasgow Outcome Scale - 5 points scale, characterizing the patients' deficits

Time frame: 1 month

Secondary Outcomes

LOS Length of Stay

length of stay in days, that patient spent in hospital/ intensive care unit

Time frame: hospitalisation time

mortality

Time frame: 1 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.